COVID-19 is an emerging, rapidly evolving situation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
Claudin-Low (CLOW) tumors are classified as a subset of triple-negative breast cancers and account for a minority of breast cancer cases. But until now, there has been little study of their unique biological features. Understanding the biology of CLOW tumors is important for designing targeted therapeutic agents to treat highly aggressive breast cancers.
The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just four days left to submit your computational algorithms. Remember, if you did not participate in sub-challenge 1, you can still participate in sub-challenge 2. Thank you for your participation and please continue to post any questions or concerns on the discussion forum.
CAR T-cells, which are immune cells reprogrammed to fight cancer, are promising novel cancer therapies to treat certain types of tumors. But, the underlying biological pathways that lead to remission or toxicity are not fully understood. In a study published in Science Signaling, CPTAC investigator (part of the Proteogenomic Translational Research Centers) Dr. Amanda Paulovich, her team, and fellow researchers at Fred Hutchinson Cancer Research Center used proteomics...
The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just two weeks left to submit your compuational algorithms. Remember, if you did not participate in sub-challenge 1, you can still participate in sub-challenge 2.
The second data release for the NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge has launched! If you did not participate in sub-challenge 1 (submission 1), you can still participate in sub-challenge 2 (submission 2).
Several ongoing Phase I clinical trials are assessing the safety and tolerability of ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-Related) inhibitors when administered alone or in combination with existing therapies. ATM and ATR are attractive therapeutic targets in oncology due to defective DNA damage response (DDR) mechanisms found in many human cancers and are thought to resolve DNA damage in cancer cells and promote tumor regression.
The security of precisionFDA users’ personal information and data is of critical importance. To strengthen the safeguards already in place, precisionFDA will be introducing several changes to achieve compliance with the FedRAMP and FISMA Moderate security standards. These changes will take effect during a service outage on the site between 5PM October 31 and 5PM EDT November 1.
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is releasing the latest proteomic discovery datasets for Uterine Corpus Endometrial Carcinoma (UCEC) and Clear Cell Renal Cell Carcinoma (ccRCC). CPTAC has previously demonstrated how proteogenomics reveals new insights into cancer biology. Because of the scientific progress already made by the program, CPTAC is leveraging its investment in proteogenomics by characterizing UCEC and ccRCC and providing publicly available proteomic data for these latest tumor types.
In addition, CPTAC has also released data on the NCI-7 cell...
Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure and an increased risk of developing certain types of cancer. The FA pathway consists of a network of 21 proteins that is specialized for repairing DNA inter-strand cross-links. Identification of monoubiquitylation (or similar) defects in this network provides an opportunity for therapeutic targeting with a high-throughput, quantitative mechanism. CPTAC investigator...
The Office of Cancer Clinical Proteomics Research of the National Cancer Institute (NCI), part of the National Institutes of Health, announces the release of a video titled, “International Cancer Proteogenome Consortium (ICPC)”. Launched during the 2018 Human Proteome Organization World Congress, the video is a call-to-action for both current and potential consortium members to share data and develop a cancer atlas representative of the diversity of people with cancer around the world.
The National Cancer Institute in partnership with the Food and Drug Administration is pleased to announce the launch of the precisionFDA NCI-CPTAC Multi-Omics Challenge. The aim of this crowd-sourced, cloud-based data challenge is to incentivize the development and evaluation of novel computational algorithms that can accurately detect and correct mislabeled samples using rich multi-omics data. The challenge runs on the precisionFDA platform,...
Multidimensional multi-omics datasets from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and similar initiatives are becoming a powerful approach to understanding the molecular basis of disease and accelerating the translation of new discoveries to patient care. While there is value in multi-omics technologies and datasets to help reach a deeper understanding of a disease and ultimately help a physician and patient determine the most appropriate...
Next-generation mass spectrometry (NGMS) has become a powerful tool for protein identification and quantification from prospectively collected fresh frozen or optimal cutting temperature embedded specimens. However, limitations due to supply, accessibility, and delay of clinical information and outcomes from prospectively collected specimens allow researchers to consider the use of banked specimens.
In biomedical research, sample mislabeling or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample transferring, sample tracking, large-scale data generation, and data sharing/management.
In recent years, proteomic technologies have emerged as invaluable tools in cancer research. Next-generation mass spectrometry (NGMS) is being used to study cancer biology, while providing the cancer research community with a growing body of biological knowledge that may lead to more effective drug design, better patient treatment options, and more accurate prognoses.
Acute myeloid leukemia (AML) is a heterogenous malignancy that stems from the production of abnormal white blood cells, platelets, or red blood cells in the bone marrow. It is estimated that 19,520 new AML cases will occur in the United States this year.
In an effort to improve rigor and reproducibility, the National Cancer Institute (NCI) Antibody Characterization Program requests cancer-related protein targets for monoclonal antibody production and distribution to the scientific community. The program from The Office of Cancer Clinical Proteomics Research provides well-characterized
Eleven experts were interviewed in a series of videos titled Perspectives in Proteomics at the Human Proteome Organization World Congress (HUPO 2017) in Dublin, Ireland this past fall.
The National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research, part of the National Institutes of Health, along with the Indian Institute of Technology Bombay (IITB) and Tata Memorial Centre (TMC) have signed a Memorandum of Understanding (MOU) on clinical proteogenomics cancer research. The MOU between NCI, IITB, and Tata Memorial Centre represents the thirtieth and thirty-first institutions and the twelfth country to join the International Cancer Proteogenome Consortium (ICPC). The purpose of the...
In an effort to provide well-characterized monoclonal antibodies to the scientific community, the National Cancer Institute (NCI) Antibody Characterization Program requests cancer-related protein targets for affinity production and distribution.